Patents Assigned to GW Research Limited
-
Patent number: 11963937Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).Type: GrantFiled: May 19, 2023Date of Patent: April 23, 2024Assignee: GW Research LimitedInventors: Geoffrey Guy, Stephen Wright, Orrin Devinsky
-
Patent number: 11944600Abstract: The present invention relates to the use of cannabinoids in the treatment of a neurodegenerative disease or disorder. In particular the cannabinoids cannabidiolic acid (CBDA) and cannabidivarin (CBDV) were able to produce neuroprotective effects in a mouse model of neurodegenerative disease. In particular these effects were associated with the symptoms associated with amyotrophic lateral sclerosis (ALS). Furthermore, the combination of the cannabinoid tetrahydrocannabinol (THC) with the drug olexisome provided a synergistic disease modifying effect in a mouse model of neurodegenerative disease. In particular these effects were associated with the symptoms associated with ALS.Type: GrantFiled: July 10, 2018Date of Patent: April 2, 2024Assignee: GW Research LimitedInventors: Benjamin Whalley, William Hind, Royston Gray, Javier Fernandez-Ruiz, Eva De Lago, Carmen Rodriguez-Cueto, Laura Garcia-Toscano, Irene Santos-Garcia
-
Patent number: 11865102Abstract: Cannabidiol (CBD) is a cannabinoid designated chemically as 2-[(IR,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol. Its empirical formula is C21H30O2 and its molecular weight is 314.46. CBD is a cannabinoid that naturally occurs in the Cannabis sativa L. plant. CBD is a white to pale yellow crystalline solid which is insoluble in water and soluble in organic solvents. The present invention encompasses the surprising recognition that certain CBD preparations which are prepared from a botanical origin are more effective in treating diseases or disorders than preparations of CBD which are synthetic or purified to the extent no other impurities in the form of other cannabinoids are present. Prior CBD compositions have been prepared such that no psychoactive components, e.g., tetrahydrocannabinol (THC), remain in the final CBD preparation. Surprisingly, the absence of such minor impurities reduces the efficacy of CBD treatment.Type: GrantFiled: November 17, 2021Date of Patent: January 9, 2024Assignee: GW Research LimitedInventors: Geoffrey Guy, Volker Knappertz, Benjamin Whalley, Marie Woolley-Roberts, James Brodie, Katarzyna Lach-Falcone, Alan Sutton, Royston Gray, Rohini Rajyalaxmi Rana
-
Patent number: 11806319Abstract: The present invention relates to a novel cannabinoid oral pharmaceutical dosage form, based on a Type IV or Type IV-like formulation, as classified using the Lipid Formulation Classification System. The formulation is contained in a container. By Type IV-like, it is meant that the formulation comprises no oil, for example no triglycerides or mixed glycerides.Type: GrantFiled: January 2, 2019Date of Patent: November 7, 2023Assignee: GW Research LimitedInventors: Jitinder Wilkhu, Johan Bender
-
Patent number: 11793770Abstract: The present invention relates to the use of 7-hydroxy-cannabidol (7-OH-CBD) and/or 7-hydroxy-cannabidivarin (7-OH-CBDV) in the treatment of epilepsy. Preferably the cannabinoid metabolites are isolated from plants to produce a highly purified extract or can be reproduced synthetically.Type: GrantFiled: September 10, 2021Date of Patent: October 24, 2023Assignee: GW Research LimitedInventors: Colin Stott, Nick Jones, Benjamin Whalley, Gary Stephens, Claire Williams
-
Patent number: 11766411Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).Type: GrantFiled: July 29, 2022Date of Patent: September 26, 2023Assignee: GW Research LimitedInventors: Geoffrey Guy, Stephen Wright, Orrin Devinsky
-
Patent number: 11752111Abstract: The present invention relates to the use of cannabidivarin (CBDV) in the treatment of autism spectrum disorder (ASD) and ASD-associated disorders such as Fragile X syndrome (FXS); Rett syndrome (RS); or Angelman syndrome (AS). In a further embodiment the invention relates to the use of CBDV in the treatment of schizophrenia. CBDV has been shown to be particularly effective in improving cognitive dysfunction in rodent models of ASD, FXS, RS, AS and schizophrenia. The CBDV is preferably substantially pure. It may take the form of a highly purified extract of cannabis such that the CBDV is present at greater than 95% of the total extract (w/w) and the other components of the extract are characterised. Alternatively, the CBDV is synthetically produced.Type: GrantFiled: April 11, 2017Date of Patent: September 12, 2023Assignee: GW RESEARCH LIMITEDInventors: Geoffrey Guy, Stephen Wright, James Brodie, Marie Woolley-Roberts, Rafael Maldonado, Daniela Parolaro, Livio Luongo, Joanna Neill
-
Patent number: 11701330Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).Type: GrantFiled: September 10, 2021Date of Patent: July 18, 2023Assignee: GW Research LimitedInventors: Geoffrey Guy, Stephen Wright, Orrin Devinsky
-
Patent number: 11684598Abstract: The present invention relates to the use of a therapeutically effective amount of cannabidiolic acid (CBDA) in the treatment of epilepsy. In one embodiment the CBDA is used in the treatment of generalised seizures, preferably tonic-clonic seizures. Preferably the CBDA used is in the form of a botanical drug substance in which the CBDA content is greater than 60%, and most preferably, it is a highly purified extract of cannabis such that the CBDA is present at greater than 95%, through 96% and 97% to most preferably, greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoids tetrahydrocannabinol (THC) or tetrahydrocannabinol acid (THCA) have been substantially removed. Alternatively, the CBDA may be synthetically produced.Type: GrantFiled: September 9, 2021Date of Patent: June 27, 2023Assignee: GW Research LimitedInventors: Colin Stott, Nicholas Jones, Robin Williams, Benjamin Whalley
-
Patent number: 11633369Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).Type: GrantFiled: August 11, 2022Date of Patent: April 25, 2023Assignee: GW Research LimitedInventors: Geoffrey Guy, Stephen Wright, Orrin Devinsky
-
Patent number: 11590087Abstract: The present invention relates to a cannabidiol (CBD) type cannabinoid compound for use as a medicament. The CBD-type cannabinoid, 6-hydroxy cannabidivarin (6-OH CBDV), is a metabolite of cannabidivarin (CBDV). The cannabinoid can be produced by synthetic means and a method for the production of 6-OH CBDV is described herein. In addition, disclosed herein are data which demonstrate the efficacy of 6-OH CBDV in a model of disease.Type: GrantFiled: May 13, 2022Date of Patent: February 28, 2023Assignee: GW Research LimitedInventors: Geoffrey Guy, Volker Knappertz, Benjamin Whalley, Marie Woolley-Roberts
-
Patent number: 11446258Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).Type: GrantFiled: September 16, 2021Date of Patent: September 20, 2022Assignee: GW Research LimitedInventors: Geoffrey Guy, Stephen Wright, Orrin Devinsky
-
Patent number: 11426362Abstract: The present invention relates to an oral formulation containing one or more cannabinoids. Preferably one or more cannabinoids dissolved in a solvent system consisting essentially of: a non-ionic surfactant and water together with other components which ensure the cannabinoids stability and the formulations palatability. Furthermore, the cannabinoid may be selected from one or more of cannabichromene (CBC), cannabichromenic acid (CBCV), cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigerol propyl variant (CBGV), cannabicyclol (CBL), cannabinol (CBN), cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV) and tetrahydrocannabivarinic acid (THCVA).Type: GrantFiled: February 15, 2018Date of Patent: August 30, 2022Assignee: GW Research LimitedInventors: Stephen Wright, Jitinder Wilkhu
-
Patent number: 11419829Abstract: The present invention relates to the use of cannabidiol (CBD) in combination with an agonist of 5-HT2B receptors. Such a combination provides protection against the adverse effects caused by agonists of 5-HT2B receptors. The invention further relates to the use of CBD in combination5 with an amphetamine or amphetamine derivative in the treatment of epilepsy. In one embodiment the CBD is used in combination with the amphetamine derivative fenfluramine to produce a significant reduction in seizures. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoid10 tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w/w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.Type: GrantFiled: October 1, 2018Date of Patent: August 23, 2022Assignee: GW Research LimitedInventors: Benjamin Whalley, Geoffrey Guy, Volker Knappertz, Royston Gray, Rohini Rana
-
Patent number: 11406623Abstract: The present disclosure provides methods of treating tuberous sclerosis complex comprising administering cannabidiol and everolimus.Type: GrantFiled: October 25, 2021Date of Patent: August 9, 2022Assignee: GW Research LimitedInventors: Geoffrey Guy, Volker Knappertz, Eduardo Dunayevich, David Critchley
-
Patent number: 11400055Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of Tuberous Sclerosis Complex (TSC). In particular the TSC is treatment resistant and is characterised by generalised seizures or focal seizures with impairment. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).Type: GrantFiled: June 7, 2021Date of Patent: August 2, 2022Assignee: GW Research LimitedInventors: Geoffrey Guy, Stephen Wright, Elizabeth Thiele
-
Patent number: 11390437Abstract: The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant.Type: GrantFiled: October 1, 2020Date of Patent: July 19, 2022Assignee: GW Research LimitedInventor: Brian Anthony Whittle
-
Patent number: 11357741Abstract: The present invention relates to the use of cannabidiol (CBD) in the treatment of focal seizures. In one embodiment the patients suffering from focal seizures are children and young adults. CBD appears particularly effective in reducing focal seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; CDKL5; Neuronal ceroid lipofuscinoses (NCL); febrile infection related epilepsy syndrome (FIRES); Aicardi syndrome and brain abnormalities in comparison to other seizure types. Significantly CBD additionally is very effective in the reduction of a sub-type of focal seizures, focal seizures with impairment.Type: GrantFiled: June 4, 2020Date of Patent: June 14, 2022Assignee: GW Research LimitedInventors: Geoffrey Guy, Stephen Wright, Orrin Devinsky
-
Patent number: 11311498Abstract: The present disclosure relates to the use of cannabidiol (CBD) in the treatment of absence seizures. In particular, the disclosure relates to the use of CBD for reducing absence seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; CDKL5; Dup15q; Jeavons syndrome; Myoclonic Absence Epilepsy; Neuronal ceroid lipofuscinoses (NCL) and brain abnormalities. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).Type: GrantFiled: June 17, 2015Date of Patent: April 26, 2022Assignee: GW Research LimitedInventors: Geoffrey Guy, Stephen Wright, Orrin Devinsky
-
Patent number: 11291631Abstract: The present invention relates to a cannabinoid containing oral solution. Preferably the oral solution comprises a cannabinoid, a lipid solvent, a sweetener and ethanol, characterised in that the sweetener is an ultrahigh potency sweetener.Type: GrantFiled: June 29, 2017Date of Patent: April 5, 2022Assignee: GW Research LimitedInventor: Harshit Shah